Citric acid
|
Basic information |
| Metabolite name | Citric acid |
 | HMDB0000094 |
 |
C00158 |
 |
311 |
| Synonyms | Citrate |
| No. of studies | 87 |
|
Basic information |
| Metabolite name | Citric acid |
| HMDB0000094 |
|
C00158 |
|
311 |
| Synonyms | Citrate |
| No. of studies | 87 |
|
Relationship between Citric acid and depression (count: 87) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Down |
| Study M049 | Type2 | xiaoyansan treatment 8-week vs. baseline | Urine | Human | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M063 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M063 | Type2 | CUMS + high dose of the sea buckthorn seed oil group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M063 | Type2 | CUMS + middle dose of the sea buckthorn seed oil group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M063 | Type2 | CUMS + low dose group of the sea buckthorn seed oil group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Down |
| Study M086 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M090 | Type1 | depressed group vs. control group | Urine | Human | Up |
| Study M090 | Type2 | depressed group 6-week treatment vs. baseline | Urine | Human | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Down |
| Study M095 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M095 | Type2 | CUMS + XCHT group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Up |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + high dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M1039 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M1039 | Type2 | CUMS + low dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M112 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M1135 | Type1 | PSD group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + low dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M510 | Type1 | LQS group vs. control group | Urine | Human | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Up |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M589 | Type1 | current depression group vs. control group | Plasma | Human | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M614 | Type2 | CUMS + resistance training group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M664 | Type1 | CSDS group vs. control group | Prefrontal cortex | C57BL/6 J mouse | Down |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Down |
| Study M749 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Up |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Down |
| Study M768 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M768 | Type2 | depression group, after vs. before fluoxetine treatment | Serum | Human | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Urine | Wistar rat | Down |
| Study M840 | Type1 | casein-rich milk group vs. control group | Urine | Wistar rat | Down |
| Study M843 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M940 | Type2 | CUMS + Chaihu group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M951 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M951 | Type2 | CUMS + paeoniflorin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Up |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |